| Dispensed a urate-lowering therapy |
This measure shows the percentage of people with identified gout who received urate-lowering therapy at least once in a year. Long-term urate-lowering therapy is used to prevent gout flares and prevent tophus formation, bony erosions and permanent disability in people with gout. Many studies have demonstrated underutilisation of urate-lowering therapy continuously and long term. |
National Minimum Dataset, Pharmaceutical Collection (PHARMS), PHO Enrolment Collection, Mortality Collection, NZ Cancer Registry, Ministry of Health, National Population Projection - Stats NZ |
Health Quality & Safety Commission | Te Tāhū Hauora |
|
| Acute hospital bed-day rate |
This measure provides details on the number of days spent in hospital for unplanned care including emergencies per 1,000. It is a measure of acute demand on secondary care. A reduction in acute demand can be an indication of effective partnership with primary and community care sectors, good hospital care and discharge planning, and/or appropriate integration of services and transitions between sectors. |
National Minimum Dataset (NMDS), Programme for the Integration of Mental Health Data (PRIMHD), Ministry of Health, National Population Projection - Stats NZ |
Health Quality & Safety Commission | Te Tāhū Hauora |
|
| Access to planned care |
This measure details the rate of people who had surgery or care that was planned in advance, as a percentage of the agreed number of events in the delivery plan. Note that values greater than 100% are possible when interventions delivered exceed the agreed number from the plan. Timely access to planned care is important for the health, wellbeing and quality of life of New Zealanders and is seen as a marker of the quality of the public hospital system. |
National Minimum Dataset (NMDS), National Non-Admitted Patient Collection (NNPAC), Planned Care Funding Schedule (PCFS), Ministry of Health |
Health Quality & Safety Commission | Te Tāhū Hauora |
|
| People report being involved in the decisions about their care and treatment |
This measure provides detail on the percentage of people who say they feel involved in their own care and treatment with their GP or nurse. Being involved in decisions about care and treatment as much as is wanted is a critical component of strong partnerships between patients and practitioners. |
New Zealand primary care patient experience survey, Te Tāhū Hauora Health Quality & Safety Commission, National Enrolment Service (NES), Ministry of Health |
Health Quality & Safety Commission | Te Tāhū Hauora |
|
| Immunisation rate for children at 24 months old |
This measure details the percentage of children who have all their age-appropriate schedule vaccinations by the time they are two years old. Timely immunisations ensure children are protected against harmful and avoidable diseases. The childhood immunisation programme is a series of vaccines that are offered free to babies and young children. The first vaccinations occur when the child is six weeks old. This programme is part of the national immunisation schedule. |
National Immunisation Register (NIR), Ministry of Health |
Health Quality & Safety Commission | Te Tāhū Hauora |
|
| People aged under 25 years able to access specialist mental health services within three weeks of referral |
This measure details the percentage of new clients aged under 25 years seen within three weeks of referral to mental health services. We know there are pressures on child and youth services, and some children and young people have to wait before accessing the help they need. The onset of serious mental illness mostly occurs before the age of 25 years, and crosses child and adolescent and adult service boundaries. It is important to focus on the specific needs of young people presenting with a first episode of illness. This indicator aims to lift performance and support more timely access for children and young people. |
Programme for the Integration of Mental Health Data (PRIMHD), Ministry of Health |
Health Quality & Safety Commission | Te Tāhū Hauora |
|
| People report they can get primary care when they need it |
This measure provides details on the percentage of people who say they receive care from a GP or nurse when they need it. |
New Zealand primary care patient experience survey, Te Tāhū Hauora Health Quality & Safety Commission, National Enrolment Service (NES), Ministry of Health |
Health Quality & Safety Commission | Te Tāhū Hauora |
|
| Ambulatory sensitive hospitalisations for adults (age range 45–64 years) |
This measure details the rate of hospital admissions for people aged 45–64 years for an illness that might have been prevented or better managed in the community. Ambulatory sensitive hospitalisations are mostly acute admissions that are considered potentially reducible through prophylactic or therapeutic interventions deliverable in a primary care setting. |
National Minimum Dataset (NMDS), Ministry of Health, Estimated Resident Population Projections, Stats NZ |
Health Quality & Safety Commission | Te Tāhū Hauora |
|
| Serum urate test within six months of urate-lowering therapy |
This measure shows the percentage of people who had serum urate testing in the six months following urate-lowering therapy dispensing. Best practice guidelines recommend that people with gout who are prescribed urate-lowering therapy should have their serum urate level monitored at least every six months. Long-term urate-lowering therapy is not recommended for people with asymptomatic hyperuricaemia. |
National Minimum Dataset (NMDS), Pharmaceutical Collection (PHARMS), PHO Enrolment Collection, Mortality Collection, NZ Cancer Registry, Ministry of Health, National Population Projection - Stats NZ |
Health Quality & Safety Commission | Te Tāhū Hauora |
|
| Regularly dispensed a urate-lowering therapy |
This measure shows the percentage of people with identified gout who received urate-lowering therapy regularly. Long-term urate-lowering therapy is used to prevent gout flares and prevent tophus formation, bony erosions and permanent disability in people with gout. Many studies have demonstrated underutilisation of urate-lowering therapy. |
National Minimum Dataset (NMDS), Pharmaceutical Collection (PHARMS), PHO Enrolment Collection, Mortality Collection, NZ Cancer Registry, Ministry of Health, National Population Projection - Stats NZ |
Health Quality & Safety Commission | Te Tāhū Hauora |
|
